Protara Therapeutics, Inc. (TARA) stock
TARANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$2.32−0.06 (-2.52%)
Close on Nov 17, 2026Market cap $137.10MP/E –Yield –
Protara Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Protara Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $53.23M, up 42.0% year over year. For fiscal 2025 it was $42.63M, up 34.5% from the year before. Over ten years it grew 13.2% a year on average. The highest annual figure on record is $42.63M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.63M | +34.5% |
| FY2024 | Dec 31, 2024 | $31.70M | +26.9% |
| FY2023 | Dec 31, 2023 | $24.99M | +48.7% |
| FY2022 | Dec 31, 2022 | $16.81M | -20.3% |
| FY2021 | Dec 31, 2021 | $21.09M | +76.0% |
| FY2020 | Dec 31, 2020 | $11.98M | +209.0% |
| FY2019 | Dec 31, 2019 | $3.88M | -67.3% |
| FY2018 | Dec 31, 2018 | $11.85M | -45.4% |
| FY2017 | Dec 31, 2017 | $21.69M | +14.9% |
| FY2016 | Dec 31, 2016 | $18.87M | +52.4% |
| FY2015 | Dec 31, 2015 | $12.38M | +92.5% |
| FY2014 | Dec 31, 2014 | $6.43M | +61.0% |
| FY2013 | Dec 31, 2013 | $3.99M | -32.4% |
| FY2012 | Dec 31, 2012 | $5.91M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $16.96M | +57.4% |
| Q1 FY2026 | Mar 31, 2026 | $13.56M | +48.3% |
| Q4 FY2025 | Dec 31, 2025 | $13.12M | +38.2% |
| Q3 FY2025 | Sep 30, 2025 | $9.59M | +18.8% |
| Q2 FY2025 | Jun 30, 2025 | $10.77M | +68.6% |
| Q1 FY2025 | Mar 31, 2025 | $9.15M | +18.1% |
| Q4 FY2024 | Dec 31, 2024 | $9.50M | +48.9% |
| Q3 FY2024 | Sep 30, 2024 | $8.07M | +29.8% |
| Q2 FY2024 | Jun 30, 2024 | $6.39M | -11.9% |
| Q1 FY2024 | Mar 31, 2024 | $7.75M | +50.7% |
| Q4 FY2023 | Dec 31, 2023 | $6.38M | +27.9% |
| Q3 FY2023 | Sep 30, 2023 | $6.22M | +79.4% |
| Q2 FY2023 | Jun 30, 2023 | $7.25M | +135.0% |
| Q1 FY2023 | Mar 31, 2023 | $5.14M | -2.4% |
| Q4 FY2022 | Dec 31, 2022 | $4.99M | +22.6% |
| Q3 FY2022 | Sep 30, 2022 | $3.47M | -15.3% |
| Q2 FY2022 | Jun 30, 2022 | $3.08M | -47.6% |
| Q1 FY2022 | Mar 31, 2022 | $5.27M | -25.2% |
| Q4 FY2021 | Dec 31, 2021 | $4.07M | +11.4% |
| Q3 FY2021 | Sep 30, 2021 | $4.09M | +46.4% |
| Q2 FY2021 | Jun 30, 2021 | $5.89M | +138.3% |
| Q1 FY2021 | Mar 31, 2021 | $7.04M | +129.7% |
| Q4 FY2020 | Dec 31, 2020 | $3.65M | +410.9% |
| Q3 FY2020 | Sep 30, 2020 | $2.80M | +154.5% |
| Q2 FY2020 | Jun 30, 2020 | $2.47M | +150.3% |
| Q1 FY2020 | Mar 31, 2020 | $3.07M | +184.4% |
| Q4 FY2019 | Dec 31, 2019 | $714.82K | -73.2% |
| Q3 FY2019 | Sep 30, 2019 | $1.10M | -53.3% |
| Q2 FY2019 | Jun 30, 2019 | $986.72K | -64.2% |
| Q1 FY2019 | Mar 31, 2019 | $1.08M | -73.5% |
| Q4 FY2018 | Dec 31, 2018 | $2.66M | -17.1% |
| Q3 FY2018 | Sep 30, 2018 | $2.35M | -77.2% |
| Q2 FY2018 | Jun 30, 2018 | $2.76M | -29.1% |
| Q1 FY2018 | Mar 31, 2018 | $4.07M | -4.1% |
| Q4 FY2017 | Dec 31, 2017 | $3.21M | -27.6% |
| Q3 FY2017 | Sep 30, 2017 | $10.34M | +113.5% |
| Q2 FY2017 | Jun 30, 2017 | $3.89M | – |
| Q1 FY2017 | Mar 31, 2017 | $4.25M | – |
| Q4 FY2016 | Dec 31, 2016 | $4.44M | – |
| Q3 FY2016 | Sep 30, 2016 | $4.84M | – |
See a number that looks wrong?